Shield Therapeutics (STX) Share Price, News & Analysis

Company Overview

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

Key Stats

• Today's Range: 8.09 to 8.46
• 50-Day Range: 2.85 to 9
• 52-Week Range: 2.10 to 9.10
• Volume: 1.97 million shs
• Average Volume: 2.77 million shs
• Market Capitalization: £85.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 15
• Consensus Rating: Buy

Shield Therapeutics Stock Analysis - MarketRank™

Shield Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Shield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Shield Therapeutics has a consensus price target of GBX 15, representing about 79.6% upside from its current price of GBX 8.35.

Amount of Analyst Coverage

Shield Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shield Therapeutics is -417.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shield Therapeutics is -417.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Shield Therapeutics has a P/B Ratio of 152.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for STX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shield Therapeutics does not currently pay a dividend.

Dividend Growth

Shield Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for STX.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Shield Therapeutics this week, compared to 0 articles on an average week.

Search Interest

45 people have searched for STX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

1 people have added Shield Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shield Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Shield Therapeutics is held by insiders.

Percentage Held by Institutions

Only 6.66% of the stock of Shield Therapeutics is held by institutions.

STX Stock Analysis - Frequently Asked Questions

How have STX shares performed this year?

Shield Therapeutics' stock was trading at GBX 2.70 on January 1st, 2025. Since then, STX stock has increased by 209.3% and is now trading at GBX 8.35.

How were Shield Therapeutics' earnings last quarter?

Shield Therapeutics plc (LON:STX) posted its quarterly earnings data on Thursday, April, 24th. The company reported ($3.00) earnings per share for the quarter. Shield Therapeutics had a negative trailing twelve-month return on equity of 470.50% and a negative net margin of 173.43%.

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Company Calendar

• Last Earnings: 4/24/2025
• Today: 9/16/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Computer Hardware
• Current Symbol: LON:STX
• CIK: N/A
• Web: www.shieldtherapeutics.com
• Phone: +44-191-5118500
• Fax: N/A
• Employees: 40,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Shield Therapeutics: GBX 15
• High Price Target: GBX 15
• Low Price Target: GBX 15
• Potential Upside/Downside: +82.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 115.88
• P/E Growth: N/A
• Net Income: -£36.28 million
• Net Margins: -173.43%
• Pretax Margin: N/A
• Return on Equity: -470.50%
• Return on Assets: -47.85%

Debt

• Debt-to-Equity Ratio: 3,691.50
• Current Ratio: 1.05
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: £41.50 million
• Price / Sales: 2.06
• Cash Flow: GBX 1.29 per share
• Price / Cash Flow: 6.36
• Book Value: GBX 0.05 per share
• Price / Book: 149.84

Miscellaneous

• Outstanding Shares: 1,041,690,000
• Free Float: N/A
• Market Cap: £85.42 million
• Optionable: Not Optionable
• Beta: 1.42